EP News: Allied Professionals
Using data on patients in the United States Renal Data System (USRDS), Siontis et al (Circulation 2018; https://doi.org/10.1161/CIRCULATIONAHA.118.035418 [Epub ahead of print], PMID 29954737) sought to assess patterns of apixaban use and outcomes related to use of anticoagulants in patients with end-stage renal disease (ESRD) and atrial fibrillation (AF). As background, patient s with ESRD have both higher risk of bleeding and higher risk of stroke with AF. The Food and Drug Administration has approved updated labeling for the use of apixaban in patients with ESRD on the basis of a small pharmacokinetic study.
Source: Heart Rhythm - Category: Cardiology Authors: Erica S. Zado Tags: EP News Source Type: research
More News: Atrial Fibrillation | Bleeding | Cardiology | Food and Drug Administration (FDA) | Heart | Stroke | Study | USA Health